FOLH1 and renal pelvis/ureter urothelial carcinoma: As for radiopharmaceuticals already available in other clinical settings, prostate specific membrane antigen (PSMA) ligand 68Ga-PSMA-11 was tested in a small pilot study of 10 patients with upper tract urothelial carcinoma and shown to be clearly inferior to FDG.